Skip to main content
RLAY
NASDAQ Life Sciences

Relay Therapeutics' Zovegalisib Triplet Shows 44% ORR, Advances to Phase 3 in Metastatic Breast Cancer

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$15.21
Mkt Cap
$2.863B
52W Low
$2.67
52W High
$17.32
52W Position info
470% above low
Off High info
12% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

RLAY has more than doubled off its 52-week low of $2.67.

Summary

Relay Therapeutics announced compelling clinical data for its zovegalisib plus atirmociclib triplet combination, leading to plans for Phase 3 development in frontline PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data showed a 44% objective response rate (ORR) in heavily pre-treated, median third-line patients, with a favorable safety and tolerability profile. This advancement to Phase 3 is a significant de-risking event and a major value driver for a clinical-stage biotech company, building on the prior Breakthrough Therapy Designation for zovegalisib. The promising efficacy and tolerability, particularly the ORR approaching current standard of care in frontline settings, suggests a strong competitive profile. The company has also secured a supply agreement with Pfizer for atirmociclib. Investors will now watch for the initiation of the Phase 3 trial, expected in early 2027, pending regulatory feedback.

At the time of this announcement, RLAY was trading at $15.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $2.67 to $17.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

RLAY - Latest Insights

RLAY
Nov 04, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $16.20 info
Change: -$1.82 (-10%) info
Market Cap: $3.725B info
RLAY
Nov 04, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $16.20 info
Change: -$1.82 (-10%) info
Market Cap: $3.725B info
RLAY
Sep 22, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.54
Real-time Price: $16.20 info
Change: -$2.34 (-13%) info
Market Cap: $3.725B info
RLAY
Aug 25, 2026, 7:43 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.88
Real-time Price: $16.20 info
Change: -$3.68 (-19%) info
Market Cap: $3.725B info
RLAY
Aug 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $16.20 info
Change: -$3.10 (-16%) info
Market Cap: $3.725B info